Skip to main content
Psychedex
Article

Etizolam Facts

Depressant; Anxiolytic; Thienodiazepine; GABA-A receptor positive allosteric modulator

Description

Etizolam is a synthetic depressant of the thienodiazepine class — a structural variant of the benzodiazepine family. It amplifies GABA — the brain's main inhibitory signal — producing anxiety relief, sedation, and muscle relaxation.

Subjective effects include anxiety suppression, sedation, muscle relaxation, and anterograde amnesia. The experience is a rapid dissolution of tension — lighter and cleaner than most benzodiazepines at equivalent anxiolytic doses.

Etizolam produces high physical and psychological dependence;[1] alone, its acute toxicity is relatively low. The dominant danger is combination with opioids — it led all benzodiazepines detected in Ontario opioid-positive death investigations from 2017–2021,[2] and genetic differences in metabolism can increase blood levels up to sixfold.[3]

Dose and durationby route · individual sensitivity varies

Oral(mg)
Threshold< 0.2 mgLight0.5 – 1 mgCommon1 – 2 mgStrong2 – 5 mgHeavy5+ mg

Starts in 15 – 30 minLasts 5 – 7 hoursAfter-effects 6 – 24 hours

Body and dependence

Acute toxicity
Low
Chronic toxicity
Moderate
Physical dependence
High
Psychological dependence
High
Withdrawal
Severe · medical supervision
Compulsive redosing
High

Tolerance

Builds
Rapid
Fully resets after
10.5 days
Carries over to
benzodiazepines; thienodiazepines; Z-drugs

Effectslikely at a common dose

Perception
none likely · 5 possible, including Spatial disorientation, Vestibular distortion, Visual acuity suppression
Body
Muscle relaxation; Sedation; +8 possible, including Motor control impairment, Dizziness, Nystagmus (eye wobbles)
Thinking
Cognitive impairment; +18 possible, including Analysis suppression, Decision impairment, Information processing suppression
Feeling
Anxiety suppression; +2 possible
Self
none likely · 9 possible, including Communication suppression, Craving, Social disconnection
Time
none likely · 2 possible, including Temporal disorientation

Who shouldn't take it

Absolute
Myasthenia gravis; Concurrent opioid use; Concurrent alcohol use; Acute angle-closure glaucoma
Relative
Respiratory insufficiency; Sleep apnea; History of substance use disorder; CYP2C19 poor metabolizer genotype with concurrent CYP3A4 inhibitor; Pregnancy; Elderly patients

Combinations60 recorded

Lethal (1)
Opioids
Dangerous (21)
Alpha-2 adrenergic receptor antagonist; Antipsychotics; Atypical antipsychotics; Benzodiazepines; Buprenorphine, Kratom; Cannabis, THC; Clonidine, Guanfacine; Gabapentin, Pregabalin; GHB, Baclofen; GHB, GBL; Local anesthetics; Naltrexone; SNRIs; Stimulants; Synthetic cannabinoids; Ibogaine; Ketamine, DXM, PCP; MAOIs; NSAIDs; Poppers (Alkyl nitrites); Poppers, Nitrates
Caution (26)
See full page: psychedex.org/substances/etizolam
Not graded (12)
Not listed never means safe.

Seek help immediately if

  • Extreme drowsiness — can't stay awake or be roused
  • Confusion, slurred speech, severe loss of coordination
  • Slow, shallow, or irregular breathing
  • Unconsciousness / unresponsive; limp, floppy body
  • Blue lips or fingertips
  • Vomiting while sedated (choking / aspiration risk)
  • Cold, clammy skin; weak pulse

What to do

  1. Try to wake them — shout, firm sternal rub
  2. If unresponsive or breathing is impaired, call emergency services
  3. Place them in the recovery position — critical, they can choke on vomit
  4. Monitor breathing continuously; be ready to give rescue breaths / CPR
  5. Never leave them alone to "sleep it off"
  6. Do not give other drugs, stimulants, or more depressants

Most depressant overdoses resolve with airway protection, breathing support, and monitoring. The danger is respiratory depression and choking on vomit — sharply worse when combined with opioids or alcohol. GHB/GBL overdoses often involve sudden deep unconsciousness and may self-resolve, but airway protection is essential.

988 Suicide & Crisis LifelineFireside Project: 62-FIRESIDE

Version r1 · Not medical advice

References

  1. [1]
    ^Nielsen S, McAuley A (2020) Etizolam: A rapid review on pharmacology, non-medical use and harms — Drug and Alcohol Review doi:10.1111/dar.13052
  2. [2]
    ^Mocanu C, Woodall KL, Solbeck P (2024) Prevalence and blood concentrations of benzodiazepines and opioids in opioid-positive death investigations in Ontario, Canada, from 2017 to 2021 — Journal of Forensic Sciences doi:10.1111/1556-4029.15463
  3. [3]
    ^Fukasawa T, Yasui-Furukori N, Suzuki A, Inoue Y, Tateishi T, Otani K (2005) Pharmacokinetics and pharmacodynamics of etizolam are influenced by polymorphic CYP2C19 activity — European Journal of Clinical Pharmacology PMID:16261363
Print version
Report an issue